Table 2.
Patents containing safranal pharmacological effects
| Patent number | Patent title | Compositions | Pharmacological usage | Reference |
|---|---|---|---|---|
| WO2015124318 | The edible composition including safranal, crocin, picrocrocin and a vitamin B complex for treating the initial phase of depression | Safranal, crocin, picrocrocin and vitamin B (including vitamin B1, B2, B3, B6, B8, B9 and B12) | Treating the initial phase of depression | (112) |
| US20100028464 | Use of saffron and/or safranal and/or crocin and/or picrocrocin and/or derivatives thereof as a satiety agent for the treatment of obesity | Saffron and/or safranal and/or crocin and/or picrocrocin and/or derivatives | Treatment of obesity | (113) |
| AU2019264659A1 | Combination therapy for cancer | Safranal and optionally topoisomerase-1 inhibitors | Treating liver cancer | (114) |
| US20200253890A1 | Suppression and Inhibition of CDC25B with Safranal-Based Formulations | A therapeutically effective amount of a composition having safranal | Treating, suppressing, or reducing the severity of hyperproliferative diseases | (115) |
| JP2020132625A | Combination therapy of safranal and sorafenib for liver cancer | Safranal or a pharmaceutically acceptable prodrug thereof and sorafenib | Treatment of liver cancer | (114) |
| US20200276133A1 | Prevention of liver cancer with safranal-based formulations | A prophylactically effective amount of safranal | Prevention of liver cancer | (116) |
| EP3446678A1 | Saffron extract and its use for the prevention of mood disorders related to depression | Safranal: 0.03% -1 % dry weight; Crocins: 3.48 % dry weight [ trans-crocin-4 (major isomer), trans-crocin-3, trans-crocin-2', cis-crocin-4, trans crocin-2, and trans-crocin-1 isomers ] | prevention of mood disorders related to depression | (117) |
| US9707203B1 | Methods of killing bacteria and preventing or treating bacterial infection with oxidation products of safranal and methods of synthesizing safranal epoxides | An effective amount of at least one oxidation product of safranal | Killing bacteria and preventing or treating bacterial infection | (118) |
| US20220218779 | Composition comprising extracts of Eucommia ulmoides, Crocus sativus and/or Magnolia officinalis and the use thereof in the treatment of sleep disorders. | A mixture consisting of an extract of Eucommia ulmoides and saffron comprising safranal and an extract of Magnolia officinalis and/or Magnolia champaca comprising honokiol | Treatment of sleep disorders. | (119) |
| WO2020229412A1 | Treatment of premenstrual syndrome and/or menstrual discomfort with a composition comprising vicenin-2 | vicenin-2 in association with one or more further ingredients such as rosmarinic acid, clerodadienols, crocin, safranal, apigenins, vitamin D and magnesium | Treatment of premenstrual syndrome (PMS) and/or menstrual discomfort | (120) |
| IN201911007661 | Broad spectrum sun protective topical formulation | Safranal entrapped spherical solid lipid nanoparticles, colored zinc oxide, colored pearl powder, Pterocarpus santalinus extract, gum acacia, Aloe vera gel, shea butter, egg oil, other emollients, antioxidant, emulsifier, chelating agent, preservative, skin nourishing and skin protective agents | Sun protective | (121) |
| WO2018108879A1 | Composition for use in treating dysphoria, depression and/or mood swings relating to premenstrual syndrome (pms) | A pollen and pistil extract derived from the Graminae and/or Pinacea family, preferably from plant material originating from Zea mays L., Secale cereale L., Dactylis glomerata L., Pinus sylvestris L. and at least one second active ingredient being a source of safranal and/or (picro)crocin. | Treating dysphoria, depression and/or mood swings relating to PMS | (122) |
| WO2022128915A1 | Extract of at least one plant of the species crocus sativus comprising a high crocin content and a low safranal content, and cosmetic use thereof as an antioxidant | At least one plant of the species Crocus sativus extracts comprising 20% by dry weight of one or more crocins and less than 0.08% by dry weight of safranal | Antioxidant | (123) |
| WO2021209455A1 | Composition for improving cognitive function | A mixture of catechin and/or epicatechin, safranal and crocetin in aglycone and/or glycosylated form | Improving cognitive function | (124) |